NCT04947267 is a Phase 2 clinical trial of 3% Mepivacaine Hydrochloride in LOCAL ANESTHESIA, sponsored by Afshan Amjad Ali.

Who is sponsoring NCT04947267?

NCT04947267 is sponsored by Afshan Amjad Ali.

What drugs are being tested in NCT04947267?

Interventions in NCT04947267: 3% Mepivacaine Hydrochloride, 2% Mepivacaine with 1:100,000 epinephrine.

What condition does NCT04947267 study?

NCT04947267 studies LOCAL ANESTHESIA.

Is NCT04947267 still recruiting?

NCT04947267 is currently completed. Last updated 1 July 2021.

Last reviewed 2021-07-01 · How we verify

NCT04947267

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Compare the Pulpal Oxygen Saturation Level After Administering Mepivacaine With and Without Vasoconstrictor

Completed Phase 2 Last updated 1 July 2021

What this trial tests

Phase 2 trial testing 3% Mepivacaine Hydrochloride in LOCAL ANESTHESIA in 60 participants. Completed in 19 November 2019.

Timeline

30 May 2018

Primary endpoint
21 September 2019

19 November 2019

Quick facts

Lead sponsor	Afshan Amjad Ali
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	diagnostic
Enrollment	60
Start date	30 May 2018
Primary completion	21 September 2019
Estimated completion	19 November 2019
Sites	1 location across Pakistan

Drugs / interventions tested

3% Mepivacaine Hydrochloride — full drug profile →
2% Mepivacaine with 1:100,000 epinephrine — full drug profile →

Conditions studied

LOCAL ANESTHESIA — all drugs for LOCAL ANESTHESIA →

Sponsor

Afshan Amjad Ali — full company profile →

Who can join

Adults 15 to 50, any sex, with LOCAL ANESTHESIA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As vasoconstrictors adversely affect pulpal hemodynamics, this study compared the pulpal oxygen saturation levels after employing inferior alveolar nerve block with 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special) and 3% mepivacaine (3% Scandonest Plain).Two groups were made with 30 patients in each group. 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special) was administered to the patients in Group A whereas 3% mepivacaine (3% Scandonest Plain) was administered to the patients in Group B. Rubber dam application, cavity preparation and composite filling was then done on the selected carious mandibular premolar. Pulpal oxygen saturation levels were recorded after administration of local anesthesia with Nellcor-550 pulse oximeter and Nellcor D-YS Multisite reusable sensor.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04947267 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Afshan Amjad Ali
Last refreshed: 1 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04947267.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing